What is the recommended treatment for presumed inflammatory colitis after excluding an infectious cause?

Treatment of Presumed Inflammatory Colitis After Excluding Infectious Causes

For presumed inflammatory colitis after infectious causes have been excluded, initiate oral aminosalicylates (mesalazine 2-4 g daily or balsalazide 6.75 g daily) for mild to moderate disease, or prednisolone 40 mg daily for moderate to severe disease requiring prompt response. 1, 2

Initial Treatment Strategy Based on Disease Severity and Extent

Mild to Moderate Disease (Extensive or Left-Sided Colitis)

First-line therapy:

• Mesalazine 2-4 g daily or balsalazide 6.75 g daily are the preferred initial agents for mild to moderately active disease extending beyond the rectum 1
• Olsalazine 1.5-3 g daily can be used but has higher incidence of diarrhea in pancolitis; reserve for left-sided disease or patients intolerant of other 5-ASA formulations 1
• Combining oral and topical 5-ASA therapy provides additional benefit, particularly for troublesome rectal symptoms 1, 2

If inadequate response within 2-4 weeks:

• Initiate prednisolone 40 mg daily 1, 2
• Taper gradually over 8 weeks according to severity and patient response; more rapid reduction increases early relapse risk 1

Moderate to Severe Disease

Immediate corticosteroid therapy:

• Prednisolone 40 mg daily should be started when prompt response is required or when high-dose 5-ASA has failed 1, 2
• Combine with 5-ASA therapy for optimal outcomes 2
• If no adequate response to oral corticosteroids within 2 weeks, advance to biologic or small molecule therapy 2

Distal Colitis (Proctitis)

Topical therapy preferred:

• Topical 5-ASA is first-line for ulcerative proctitis 2
• Add or substitute oral 5-ASA or topical corticosteroids if topical 5-ASA fails or is not tolerated 2
• Refractory proctitis may require oral corticosteroids, topical tacrolimus, JAK inhibitors, S1P agonists, or biologic therapy 2

Steroid-Dependent or Refractory Disease

Steroid-sparing immunomodulators:

• Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day for patients with chronic active steroid-dependent disease 1
• Long-term corticosteroid use should be avoided 1

Advanced therapies for steroid failure:

• Biologic monoclonal antibodies (anti-TNF agents like infliximab, anti-α4β7 integrin vedolizumab, anti-IL-12/23 ustekinumab) 3
• JAK inhibitors (tofacitinib) or S1P modulators (ozanimod) 3
• These should be initiated if corticosteroid taper is unsuccessful or to avoid repeated corticosteroid courses 2

Acute Severe Ulcerative Colitis (Hospitalized Patients)

Intravenous corticosteroids:

• Intravenous methylprednisolone 40-60 mg/day (or equivalent) is the first-line treatment 4
• Higher doses provide no additional benefit and should be avoided 4
• Assess response after 3-5 days using stool frequency, C-reactive protein, and albumin levels 5

Rescue therapy for corticosteroid-refractory disease (after 3-5 days):

• Infliximab 5 mg/kg or cyclosporine 2-4 mg/kg/day are equally effective rescue options 4
• Both agents show comparable short-term colectomy rates in head-to-head trials 4

Adjunctive measures:

• Avoid adjunctive antibiotics unless documented gastrointestinal or extra-intestinal infection is present 4
• Initiate thromboprophylaxis 5
• Correct fluid, electrolyte, and nutritional deficiencies 5

Surgical intervention:

• Consider colectomy for colonic perforation, toxic megacolon, or clinical deterioration despite optimal medical therapy 4, 5
• Surgery should be performed before serum lactate exceeds 5.0 mmol/L 6

Critical Management Principles

Avoid these pitfalls:

• Never use antiperistaltic agents or opiates in inflammatory colitis, as they can precipitate toxic megacolon 7, 6
• Do not continue intravenous corticosteroids beyond 7 days in non-responders 4
• Corticosteroids are not appropriate for long-term maintenance therapy 1, 2

Maintenance strategy:

• Continue the agent that successfully induced remission (except corticosteroids) 2
• Purine analogues (azathioprine/mercaptopurine) are effective for maintenance but require induction with another agent 2
• Treatment goal has shifted from clinical response to achieving biochemical, endoscopic, and histologic remission 2

Monitoring requirements:

• Assess treatment response using clinical activity indices (Truelove & Witts' or Simple Clinical Colitis Index) 1
• Monitor biomarkers of inflammation (fecal calprotectin) 3
• Perform colonoscopy at 8 years from diagnosis for dysplasia surveillance 3